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Structured abstract 
Background: Tetralogy of Fallot (TOF), the most frequent cyanotic congenital heart disease, 
is associated with a wide range of intra- and extracardiac phenotypes. In order to get further 
insight into genotype-phenotype correlation we comprehensively investigated a large cohort 
of 230 unselected patients with TOF.  
Methods and Results: We studied 230 patients with TOF by karyotyping, comprehensive 
22q11.2 deletion testing and sequencing of TBX1, NKX2.5 and JAG1, as well as molecular 
karyotyping in selected patients. We found pathogenic genetic aberrations in 42 patients 
(18%), with 22q11.2 deletion as the most common diagnosis (7.4%), followed by trisomy 21 
(5.2%) and other chromosomal aberrations or submicroscopic copy number changes (3%). 
Mutations in JAG1 were detected in three patients with Alagille syndrome (1.3%), while 
NKX2.5 mutations were seen in two patients with non-syndromic TOF (0.9%). One patient 
showed a recurrent polyalanine stretch elongation within TBX1 for which we show that this 
represents a true mutation resulting in loss of transcriptional activity due to cytoplasmatic 
protein aggregation.  
Conclusion: We show that 22q11.2 deletion represents the most common known cause of 
TOF and that the associated cardiac phenotype is distinct for obstruction of the proximal 
pulmonary artery, hypoplastic central pulmonary arteries and subclavian artery anomalies. 
Atrioventricular septal defect associated with TOF is very suggestive of trisomy 21 and 
almost excludes 22q11.2 deletion. We report a further patient with a recurrent polyalanine 
stretch elongation within TBX1 and for the first time link TBX1 cytoplasmatic protein 
aggregation to congenital heart defects. 
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Abstract 
Tetralogy of Fallot (TOF), the most frequent cyanotic congenital heart disease, is associated 
with a wide range of intra- and extracardiac phenotypes. We investigated genotype-phenotype 
correlation in a large cohort of 230 unselected patients with TOF, in whom we performed 
karyotyping, comprehensive 22q11.2 deletion testing and sequencing of TBX1, NKX2.5 and 
JAG1, as well as molecular karyotyping in patients with TOF and otherwise unexplained 
mental retardation.  
We found pathogenic genetic aberrations in 42 patients (18%), with 22q11.2 deletion as the 
most common diagnosis (7.4%), followed by trisomy 21 (5.2%) and other chromosomal 
aberrations or submicroscopic copy number changes (3%). Mutations in JAG1 were detected 
in three patients with Alagille syndrome (1.3%), while NKX2.5 mutations were seen in two 
patients with non-syndromic TOF (0.9%). One patient showed a polyalanine stretch 
elongation within TBX1 which was previously reported as variant of unknown significance in 
a patient with isolated interruption of the aortic arch. We show that this represents a true 
mutation resulting in loss of transcriptional activity due to cytoplasmatic protein aggregation, 
for the first time linking the latter to congenital heart defects. The cardiac anomalies of this 
patient fit into the spectrum of 22q11.2 deletion, and were distinct for obstruction of the 
proximal pulmonary artery, hypoplastic central pulmonary arteries and subclavian artery 
anomalies. Atrioventricular septal defect  associated with TOF was very suggestive of trisomy 
21 and was absent in 22q11.2 deletion. 
 
Keywords: 22q11.2, tetralogy of Fallot, TBX1, polyalanine stretch elongation 
  
4 
Introduction  
Tetralogy of Fallot (TOF), is estimated to occur in 3.3 per 10 000 live births and accounts for 
6.8% of all congenital heart defects.[1] Trisomy 21 [OMIM 190685] and 22q11.2 deletion 
[OMIM 188400, 192430, 611867] are the most frequent associated genetic anomalies. The 
microdeletion within chromosomal band 22q11.2 is associated with a variety of 
syndromes,[2-4] including DiGeorge and Shprintzen (velocardiofacial) syndromes 
(DGS/VCFS; OMIM 188400 and 192430). The majority of patients harbour a deletion of 
either 3 or 1.5 Mb.[5] Of the more than 40 commonly deleted genes, Tbx1 is the only gene 
that, after an extensive functional analysis in the mouse, has been found to be 
haploinsufficient with a convincingly similar phenotype to the human syndrome.[6] TBX1 
missense and truncating mutations were found in up to 30% of non-deleted patients with 
DGS/VCFS phenotype,[7-9] while mutational screening in smaller cohorts of patients with 
isolated TOF failed to reveal TBX1 mutations,[10, 11] or reported rare variants of unknown 
significance.[12] In contrast, mutations in the NKX2.5 gene located in 5q35, were reported in 
4% of nonsyndromic TOF patients.[13, 14] Mutations of JAG1 (20p12) cause Alagille 
syndrome showing clinical overlap with 22q11.2 deletion including right heart 
abnormalities.[15] Isolated TOF was also reported to be caused by JAG1 mutations in one 
large pedigree[16] and in two nonfamilial cases.[17] To assess the incidence and to evaluate 
genotype-phenotype correlation of these potentially frequent causes of TOF, we performed 
chromosomal analysis, comprehensive 22q11.2 microdeletion testing and sequencing of 
TBX1, NKX2.5 and JAG1 in 230 unselected patients with TOF. 
 
 
Patients and methods 
Patients were recruited prospectively in two tertiary centers from 1/2003 to 6/2007. All 
patients presenting in cardiology units of Erlangen and Tuebingen with TOF (excluding 
children with pulmonary atresia and ventricular septal defect (PAVSD) but including those 
with absent pulmonary valve (APV)) were approached. Of a total of 236 patients 230 
consented to participate in the study (103 female, 127 male, median age 9.9 years). The study 
protocol was approved by the ethical committees of both medical faculties. Written informed 
consent was obtained from the parents and all patients >11 years of age. A questionnaire was 
filled out at presentation, stating social situation and previous medical history (hearing and 
speech development, frequency of infections, seizures, non cardiac surgeries, education, 
profession). Mental development was classified according to Goldmuntz et al depending on 
neuropediatric evaluation or special care during pre-school or school service.[18] The 
documentation included the main clinical features including neurologic, otolaryngeal, 
urogenital, skeletal and craniofacial anomalies. Frequent upper respiratory tract infections 
were defined as > 4 infections per year.[19] The cardiac phenotype was characterized on the 
basis of angiocardiographies in 218 and echocardiography in all patients. Differences in 
frequencies were evaluated by chi square test for categorical variables and by Student’s 
unpaired t-test for continuous variables.  
 
Genetic testing 
Chromosomal analysis was performed after GTG banding at a 450-500 banding resolution 
(ISCN 2005) from cultured lymphocytes following standard procedures. Fluorescence in situ 
hybridisation (FISH) analysis was performed on metaphase spreads with 10 DNA probes 
covering the common and atypical deletion intervals as described earlier:[5] 6E8 (D22S427), 
51H3 (D22S1649), 70A2 (D22S1694), PAC 140D4 (TUPLE1/HIRA), co23 (UFD1L), D0832 
(COMT), 48c12 (D22S264), cHKAD26 (D22S935), cosmid 109G12 (109G12-1), BAC 
438P22 (D22S425). In 13 patients in whom parents agreed only to the collection of saliva or 
in whom the lymphocyte cultures failed, multiplex-ligation dependent probe amplification 
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(MLPA) with the 22q11.2 MRC-Holland kit P023 was performed on DNA extracted from 
peripheral blood or saliva with standard methods. In patients with mental retardation, normal 
conventional or no karyotype and normal molecular testing (total 19 patients), molecular 
karyotyping using an Affymetrix GeneChip 100 K SNP array was performed.[20] TBX1, 
NKX2.5 and JAG1 mutational analysis in patients with normal karyotype was performed by 
direct sequencing of PCR amplificates using intronic primers for all coding exons (table 1).  
 
Functional testing 
Constructs. We used a TBX1 wild-type expression construct, containing the complete cDNA 
of human TBX1 isoform C, and a 2xTtkGL2 reporter construct, containing two palindromic 
T-box binding sites inserted upstream of the tk promoter.[9] The P290S mutation was inserted 
using the Quick Change Site Directed Mutagenesis Kit (Stratagene). The dup30-plasmid was 
constructed by replacing the respective part of the TBX1 gene in the expression vector by a 
fragment containing the dup30, that was amplified from the patient’s DNA. The complete 
cDNA of NKX2.5 was amplified from cDNA of fetal spleen (Clontech) with RT-PCR and 
cloned into the pcDNA3.1 expression vector (Invitrogen). Mutagenesis was performed using 
the Quick Change Site Directed Mutagenesis Kit (Stratagene). As a binding site for NKX2.5 
the reported proximal promoter consisting of the adjacent 135 base pairs upstream of the atrial 
natriuretic factor gene (ANF)[21] was amplified from DNA of a healthy individual and 
cloned into a pGL3 luciferase reporter vector (Promega).  
 
Luciferase assays. As described previously, we used JEG3 cells which are derived from 
chorioncarcinoma for the transcriptional reporter assay, since the wildtype did not activate t-
boxes in HEK293 cells, which apparently lack transcriptional co-factors necessary for proper 
TBX1 function.[9] For the NKX2.5 reporter assay HEK293 and COS7 cells were cultivated 
in RPMI medium containing 10% FCS and then like for the TBX1 assay were transiently co-
transfected with 100 ng of the wild-type or mutant constructs, 1µg of the reporter construct 
and a renilla luciferase vector used for normalization. Cells were harvested 48 h after 
transfection and luminescence measurements were performed with a Dual Luciferase Kit 
(Promega) and a luminometer.  
 
Real-time PCR. We performed a quantitative real-time PCR assay to analyze mRNA levels of 
TBX1 wild-type and mutants in transfected JEG3 cells.[9] Cells were cotransfected in 
duplicate with the TBX1 wildtype or mutant vector and a renilla luciferase vector and were 
harvested after 48 h. Quantitative multiplex PCR was performed with a tagged-TBX1-specific 
TaqMan probe and a control probe detecting renilla luciferase, to normalize for transfection 
efficiency. Data from quadruplicate measurements were analyzed using the DDCt method. 
 
Immunohistochemistry was performed in JEG3-cells transfected with the empty CMV vector, 
the construct containing the wildtype and the vector containingthe mutant HA-tagged TBX1 
with a primary Anti-HA antibody (Sigma-Aldrich) and a secondary, Cy3 labeled Anti Rabbit 
Antibody (Abcam) 24h after transfection. 100 Cy3 positive cells each were microscopically 
analysed for staining pattern. Immunostaining was performed as described.[22] 
 
Results 
Results of genetic testing and associated phenotypes are summarized in tables 2-5. FISH 
analysis showed deletion of probes 51H3, 70A2, PAC 140D4, co23, D0832, 48c12 and 
cHKAD26 indicating the common 3 Mb deletion in 16 patients, and deletion of the probes 
51H3, 70A2, PAC 140D4, co23 and D0832 indicating the proximal 1.5 Mb deletion in one 
patient. Details about the four submicroscopic imbalances detected by molecular karyotyping 
were reported elsewhere.[20]  
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We found two unknown variants in TBX1 and two in NKX2.5, as well as the known NKX2.5 
missense mutation R25C in further two patients. The JAG1 missense mutation R937Q was 
reported before in a patient with Alagille syndrome[23] and excluded by us in 284 normal 
control individuals. The NKX2.5 mutation R25C was supposed to be functionally relevant but 
with low penetrance.[13, 24, 25] The two unknown NKX2.5 variants C270Y and V315L 
(table 3) were not detected in 280 control individuals and were evolutionary conserved for 
many but not all species. Although functional testing using a transcriptional reporter assay did 
not reveal a relevant reduction in transcriptional activity, we can not exclude that they might 
cause alterations not detectable by this assay (Figure 1). Likewise, the TBX1 variant P290S 
was evolutionary conserved for many but not all species and was not observed in 174 control 
individuals, but was found to be inherited from the healthy father and showed no alteration in 
the transcriptional reporter assay (Figure 2). The TBX1 gross insertion of 30 bp within exon 
9c (GCCGCGGCCGCCGCCGCCGCTGCCGCAGCT; c.1399-1428dup30) was determined 
by cloning the aberrant PCR fragment and sequencing of clones. It was excluded in 185 
control individuals as well as in the patient’s mother. The father, who was a smoker and obese 
and deceased at the age of 40 years after cardiac infarction. Despite normal mRNA levels as 
revealed by RT-PCR, the transcriptional reporter assay showed severely reduced 
transcriptional activity of the mutant construct containing the c.1399-1428dup30 (Figure 2). 
Since this insertion leads to the expansion of a polyalanine tract, we assumed that it might 
lead to aggregation of the protein. We therefore performed immunofluorescence studies 
which indeed demonstrated aggregation of the protein in the cytoplasma (Figure 3).  
 
Comparison of cardiovascular and extracardiac phenotype in patients with and without 
22q11.2 deletion.  
There was no significant difference in z-scores for weight (p=0.16 Mann-Whitney-Test), but 
there was for height (p=0.045) between patients with 22q11.2 deletion and those without 
detectable genetic abnormality (table 4). Mild mental retardation was present in most of the 
deleted (82%) but only in a minority of genetically normal patients (15%, p<0.001). 
Velopharyngeal insufficiency (47 vs. 2%, p<0.001) was predominantly observed in patients 
with 22q11.2 deletion, while upper respiratory tract infections, palatal, skeletal and 
genitourinary abnormalities did not reach statistical significance. The cardiovascular 
phenotype differed with respect to the pulmonary artery (PA) anatomy and the aortic arch 
vessels (table 5):  8/34 patients (24%) with juxtaductal coarctation or hypoplastic PA had 
22q11.2 deletion, while the incidence of this microdeletion among the remaining patients was 
5% (9/196) (p<0.001). Similar findings were observed for subclavian artery anomalies 
(SAA): 9/31 patients (29%) with SAA had the deletion, but only 8/199 (4%) without SAA 
(p<0.001). 22q11.2 deletion was independent of the laterality of the aortic arch (p=0.14). The 
most frequent anomaly of the subclavian artery was aberrant origin from the descending aorta, 
followed by isolation, which was found exclusively in combination with right aortic arch 
(RAA) (7 patients). Cervical origin of the right subclavian artery (CORSA) was detected in 
one patient with 22q11.2 deletion. The shape of the infundibulum did not differ between both 
groups and most of the patients had combined – valvular and infundibular stenoses. Coronary 
artery anomalies, patent ductus arteriosus in the neonatal period, MAPCAs, pronounced 
dextroposition of the aorta (> 50% from right ventricle), or APV were not specifically 
associated with the 22q11.2 deletion. None of our patients with 22q11.2 deletion had 
associated atrioventricular septal defect (AVSD). Patients with 22q11.2 deletion showed 
facial features compatible with the DiGeorge-/Shprintzen syndrome phenotype. 
 
Phenotype of patients with TBX1, NKX2.5 or JAG1 mutations  
Patients with functionally proven mutations in TBX1, NKX2.5 or JAG1 did not differ 
significantly from the non-mutated patients in height and weight (table 4). While patients with 
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TBX1 or NKX2.5 mutations showed no specific facial dysmorphism and attended regular 
schools, all 3 patients with JAG1 mutations had indicative facial gestalt and mild or severe 
mental retardation. The female patient with the TBX1 c.1399-1428dup30 mutation was born 
after an uneventful pregnancy at 40 weeks of gestation to healthy unrelated parents of Turkish 
origin. Birth measurements were 3250g (weight), 51cm (length), and 34cm (head 
circumference) [proportionate within normal ranges for Turkish percentiles] and APGAR 
scores were reported 9/10/10.[26] TOF with APV and isolation of the left PA was corrected at 
the age of 3 years. Frequent infections were reported during early childhood, but all regular 
vaccinations were tolerated without problems. During puberty she developed scoliosis. 
Psychomotor development was normal and the girl attended secondary school. At the age of 
20 years her height was 157cm (3rd-10th centile), weight was 56kg (25th-50th centile), head 
circumference was 52cm (3rd-10th centile). Her facial gestalt was not indicative of 22q11.2 
deletion (Figure 4). She had some broadening of the uvula and small teeth. 
Among our group of six patients with bona fide mutations she was the only one with 
additional muscular VSD. Two out of 3 patients with JAG1 mutations had peripheral 
pulmonary stenoses typical for Alagille syndrome. APV in association with TOF was neither 
characteristic for the classical 22q11.2 deletion (1 patient) nor for NKX2.5 and JAG1 
mutations. The patient with TBX1 mutation had APV with isolated left PA.  
 
Phenotype of TOF patients with Down syndrome 
Patients with Down syndrome were significantly lower in z-scores for height and weight 
(p<0.0001) than the remaining patients. Three of the 12 patients had AVSD (table 5). No 
stenoses of bifurcation or peripheral PA occurred in patients with Down syndrome, who 
showed neither MAPCAs nor abnormal coronaries. All but one had left aortic arch (LAA), 
and one with LAA had an aberrant subclavian artery.  
 
Discussion 
Genetic findings 
In contrast to our findings of cytogenetically visible chromosomal abnormalities in 6.5% 
(15/230), previous population based studies from the 1980s and early 1990s have documented 
such abnormalities in as much as 12-13% of patients with TOF.[27, 28] Since the common 
trisomies of chromosomes 13, 18 and 21 account for the vast majority of aberrations in the 
older studies, the significant difference can be explained by the lack of patients with trisomy 
13 and 18 and the decrease of children with trisomy 21 in our cohort. Nowadays these 
trisomies are frequently detected and aborted prenatally when associated with complex heart 
defects. The Baltimore-Washington Infant study included 236 patients with TOF and reported 
chromosomal abnormalities in 11.9%, Mendelian syndromes in 2.5%, non-Mendelian 
associations in 4.6%, multiple anomalies in 2.1% and organ defects in 11%.[29]  With the 
introduction of FISH, and molecular karyotyping, it became evident, that a significant number 
of patients with TOF had 22q11.2 deletion or other syndromes caused by submicroscopic 
chromosomal imbalances. The latter were found in 21% of our patients with TOF and mental 
retardation investigated by molecular karyotyping (4/19), which is in line with the reported 
finding of 17% of submicroscopic chromosomal imbalances in patients with congenital heart 
defects selected for a 'chromosomal phenotype’.[30]  
The reported frequency of 22q11.2 deletion in TOF varies between 6 and 23%. [31-39] This 
variability can be explained at least partially by inclusion or exclusion of patients with 
PAVSD and MAPCAs, the extreme variant of the anatomic spectrum of TOF, since the 
incidence of 22q11.2 deletion is significantly higher in the latter group.[36, 40] In our study 
of TOF patients (excluding those with PAVSD) the incidence of 22q11.2 deletion was 7.4%, 
representing the most frequent genetic abnormality. There is some bias however, since we 
recruited patients of all age groups therefore neglecting some patients who died younger. All 
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but one patient had the classical 3 Mb deletion and none showed an atypical distal deletion, 
which apparently causes an overlapping but distinct phenotype.[5, 41, 42]  
 
So far mutations of TBX1  were reported in 5 independent families with variable features of 
the DiGeorge/Shprintzen/VCFS spectrum.[7-9] In our large cohort we evidenced for the first 
time that intragenic TBX1 mutations may cause non-syndromic TOF. The insertion of 30 bp 
within exon 9c of TBX1 (c.1399-1428dup30), detected in one patient with unsuspicious facial 
gestalt and scoliosis, was previously reported as an unclear variant in a patient with isolated 
interruption of the aortic arch.[12] We were able to show, that this in frame polyalanine 
stretch expansion results in almost complete loss of transcriptional activity due to 
cytoplasmatic aggregation of the mutant protein. This finding adds a novel pathogenetic 
mechanism of TBX1 mutations to the formerly known haploinsufficiency, gain of function or 
loss of nuclear localization signal.[20, 43]  
While expansions of polyglutamine repeats have been known as cause for a variety of 
neurodegenerative diseases, only recently mitotically stable expansions of alanine tracts 
particularly in transcription factor genes emerged as a disease mechanism in congenital 
malformations, skeletal dysplasia and nervous system anomalies.[44] A common mechanism 
seems to be enhanced degradation due to protein misfolding and/or aggregation resulting in 
cellular dysfunction. Like we found in TBX1, for most of the known transcription factors 
associated with polyalanine stretch expansion disorders, cytoplasmatic accumulation and 
cytoplasmatic and nuclear aggregation of the mutant protein could be observed.[45] Our 
novel finding of pathogenetic polyalanine stretches in TBX1 though, for the first time links 
this mechanism to the etiology of congenital heart defects. A genotype-phenotype correlation 
with polyalanine expansions causing a milder phenotype than other mutations was reported 
for ARX, RUNX2, FOXL2 and PHOX2B.[44] Since in contrast to patients with TBX1 point 
mutations, both currently known patients with the TBX1 polyalanine expansion [12] do not 
show the classical 22q11.2 deletion phenotype,  it is tempting to speculate about a similar 
genotype-phenotype. 
 
 In contrast to earlier studies reporting NKX2.5 mutations in 1.7-4% of patients with TOF,[13, 
14, 46, 47] we found only the low penetrant R25C variant in 0.9% of all patients and in 1% of 
patients without other diagnoses. We cannot exclude though, that the rare variants C270Y and 
V315L which were not detected in 280 control individuals and showed no functional 
impairment in our transcriptional assay may cause alterations not detected by our testing 
system. Though a report on a JAG1 mutation segregating with isolated TOF in a family[16] 
and two cryptic mutation reports indicated a possible role in isolated TOF,[17] our systematic 
study showed JAG1 mutations only in patients with clinical diagnosis of Alagille syndrome.  
 
Extracardiac and cardiac phenotype of 22q11.2 deletion 
Ryan and colleagues reported that one third of deleted patients, irrespective of associated 
cardiac anomalies, were below the 3rd percentile for either height or weight, suggesting a 
strong link between growth retardation and 22q11.2 deletion.[3] Our study excludes the bias 
of comparing patients with cardiac anomalies to those without and found only a tendency 
towards lower z-scores for weight and a weak significance for lower height in 22q11.2 
deleted patients. Corrective surgery in patients with TOF results in significant catch up 
growth of weight and height within two years.[48] The majority of our patients were beyond 
this postoperative interval, explaining why no marked differences were found, even compared 
to normal values of patients without cardiac defect. Learning and behavioural difficulties  
were identified as significant discriminators between deleted and non-deleted adults with 
congenital heart disease (79 vs. 44%),[49] which is in line with the finding of mild mental 
retardation or need for special care during school documented in 82% of our patients with 
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22q11.2 deletion. As learning and behavioural difficulties were significantly less frequent in 
our patients without genetic aberration and since previous studies included deleted patients 
without congenital heart disease[3] mental retardation can be attributed to a large extent to the 
genetic disorder. While velopharyngeal insufficiency was present in 47% of patients with 
22q11.2 deletion, there was no significant difference in the incidence of frequent infections, 
impaired hearing, cleft palate and genitourinary anomalies. . 
 
In our cohort SAA contralateral to the side of the aortic arch represented the undisputable 
cardiovascular feature of 22q11.2 deletion and discriminated significantly between patients 
with and without the deletion. The incidence of SAA among children with 22q11.2 deletion in 
our study (53%) was similar to the  previously reported among 22q11.2 deletion patients with 
PAVSD (57%) or truncus arteriosus (50%) but lower than in children with interrupted aortic 
arch (75)%. [35] [50, 51] According to the pioneering work of Kutsche and van Mierop SAA 
contralateral to the aortic arch can be explained by unilateral impairment of development of 
the respective 4th aortic arch. Resulting SAA include aberrant origin from the descending 
aorta, isolation, distal ductal origin from the pulmonary artery, and cervical origin.[52] The 
latter anomaly has been described exclusively in patients with 22q11.2 deletion,[51] an 
observation further supported by the present study. The association of SAA with 22q11.2 
deletion is of clinical significance, since echocardiography achieves a high sensitivity in the 
detection of these anomalies, and allows in patients with CORSA to establish the clinical 
diagnosis of 22q11.2 deletion.[53]  
Our study revealed anomalies of the PA in patients with TOF to be significantly associated 
with 22q11.2 deletion. Almost 50% of patients with 22q11.2 deletion had either juxtaductal 
PA coarctation resulting from abnormal insertion of the arterial duct, or hypoplastic PA as 
compared to 11% of nonsyndromic patients. This confirms previous observations of 
anomalous central PA in patients with 22q11.2 deletion both with normal intracardiac 
anatomy and PAVSD.[54, 55] This is of significant clinical importance, as central PA 
hypoplasia has been found to be an independent predictor of mortality after surgical 
correction of TOF.[56, 57] Contrarily, MAPCAs,  associated with 22q11.2 deletion in patients 
with PAVSD [58], were no indicator for this deletion in TOF patients with patent pulmonary 
valve. Therefore hypoplastic PA appear as a key predictor of 22q11.2 deletion both in TOF 
and in PAVSD.  
There was no distinctive pattern of intracardiac anatomic features in 22q11.2 deletion. 
However none of our 4 patients with TOF and AVSD and none of the 64 patients investigated 
by Vergara et al. had 22q11.2 deletion confirming that AVSD almost excludes 22q11.2 
deletion. [59-61] 
APV a distinct variant of TOF is characterized by absent or rudimentary pulmonary valve 
cusps and massive dilation of the PA. Johnson et al. found a specifically high incidence of 
22q11.2 deletion (6/8 patients) among these children.[62] To the best of our knowledge our 
study represents the largest cohort of patients with APV with genetic screening. Only 1/10 
had 22q11.2 deletion, while another patient had a mutation in TBX1. Since the latter had only 
few extracardiac anomalies, TBX1 mutations might explain familial occurrence of 
nonsyndromic TOF and APV in whom only 22q11.2 deletion was excluded.[63]  
 
Comparison of cardiac phenotype between 22q11.2 deletion and TBX1 
Our patient with TBX1 mutation had an additional VSD and TOF with APV, neither of which 
where common features of 22q11.2 deletion in our cohort. In Tbx1 deficient mouse models 
short and narrow outflow tracts were described, but not an isolated and hypoplastic left PA. 
To date, there are no reports of humans with mutations in TBX1 and isolated PAs, however, 
detailed descriptions of the cardiac phenotypes are lacking in the small number of previously 
reported patients. Recent studies in mice lacking Tbx1 have displayed severe defects in the 
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development of the pharyngeal derivates leading to abnormal coronary artery patterning. 
None of our patients with 22q11.2 deletion or the patient with TBX1 mutation had coronary 
anomalies.[64]  
 
Cardiac phenotype in Down syndrome   
Our study confirmed previous results that about 25% of patients with TOF and Down 
syndrome have AVSD and in children with TOF and associated AVSD the presence of 
genetic syndromes, mostly Down syndrome, is very high (>85%).[59]. In our study patients 
with Down syndrome did not present coarctation of the PA, MAPCAs or coronary artery 
abnormalities. Furthermore our study confirmed , that pronounced dextroposition of the aorta 
is very rare in patients with Down syndrome.[59] Our finding of a single patient with Down 
syndrome and SAA is in line with previous data showing SAA in 1 out of 43 patients.[59] 
Thus, TOF in Down syndrome seems to be associated with a relatively uniform cardiac 
phenotype. Interestingly, in one patient with Down syndrome, TOF and SAA, co-occurrence 
of 22q11.2 deletion and trisomy 21 mosaicism was reported.[65] 
 
Conclusions 
We found the common 22q11.2 deletion to represent the most frequent genetic diagnosis in 
patients with TOF, followed by Down syndrome. Atypical proximal deletions in 22q11.2 as 
well as mutations in TBX1, NKX2.5 and JAG1 are far less frequent. We were able to show, 
that intragenic TBX1 mutations may cause nonsyndromic TOF and demonstrated a novel 
pathogenetic mechanism of TBX1 mutations with loss of transcriptional activity due to 
aggregation of the mutant protein. Submicroscopic chromosomal imbalances detectable by 
molecular karyotyping seem to play a major role in patients with TOF and mental retardation, 
although total numbers were small and comparison between groups had low power. Results 
from cardiovascular phenotype - genotype correlation of our study may be used to perform 
focused testing in high risk cohorts defined by prenatal or postnatal echocardiography. AVSD 
associated with TOF is very suggestive of trisomy 21 and almost certainly excludes 22q11.2 
deletion. Our postnatal study could not confirm previous prenatal observations, that SAA are 
frequently associated with trisomy 21.[66, 67] SAA and obstruction of the proximal left or 
right PA at the insertion of the ductus arteriosus as well as hypoplastic central PAs are 
associated with an increased incidence of 22q11.2 deletion. While it is probably impossible to 
discriminate the latter patients by fetal echocardiography there is increasing experience with 
the prenatal diagnosis of aortic arch anomalies and SAA, [66, 67] which may be helpful to 
recoginze those fetuses at rist for 22q11.2 deletion.  
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Figures  
 
 
Figure 1. Transcriptional activation of a luciferase reporter construct by wild-type (WT) and 
mutant NKX2.5. HEK cells were co-transfected with the ANF promoter reporter construct, 
containing NKX2.5 binding sites, and either a CMV control vector, the NKX2.5 wild-type 
construct, or the mutant constructs. In comparison to the CMV vector, wild-type NKX2.5 
results in a 4-fold increased activation of the luciferase reporter. While the positive control 
N188K showed reduced transcriptional activity as reported before[25, 68], our variants 
C270Y and V315L showed no altered activity compared to the wildtype in this assay. Results 
are normalized for transfection efficiency to a cotransfected renilla luciferase vector and 
expressed as average values ± SEM of two independent transfections. Results were confirmed 
in a second cell-line (COS7, data not shown). 
 
 
 
Figure 2.  A, Transcriptional activation of a luciferase reporter construct by wild-type (WT) 
and mutant TBX1C. JEG3 cells were co-transfected with the 2xTtkGL2 reporter construct, 
containing T-Box binding elements, and either a CMV control vector, the TBX1C wild-type 
construct, or the mutant constructs. In comparison to the CMV vector, TBX1C shows a 50-
fold increased activation on the luciferase reporter. While the paternally inherited missense 
variant P290S does not show any alteration in transcriptional activity compared to the wild-
type, the c.1399-1428dup30 mutant shows a lack of transcriptional activation, thus 
demonstrating loss of function. Results were normalized for transfection efficiency to a co-
transfected renilla luciferase vector and expressed as average values ± SEM of three 
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independent transfections. Results were confirmed in a second experiment with triple 
transfections.    
B, Expression of wild-type (WT) and mutant TBX1C in JEG3 cells. In order to investigate 
possible differences in TBX1 expression as the cause of the lack of activity in the 30bp dup 
mutant, mRNA levels of TBX1C wild-type and mutants were analyzed by quantitative RT-
PCR using a probe specific to the tagged transcript in RNA extracted from the cultured cells.  
No altered expression was observed for the mutants in comparison to the wild type. Results 
were normalized for transfection efficiency against the co-transfected renilla vector and 
expressed as average value ± SEM of quadruplicate measurements of two independent 
transfections, respectively.   
 
 
 
Figure 3. Representative results of immunhistochemistry of TBX1C wild-type and loss of 
function mutants. JEG3 cells were transfected with either an empty CMV vector, TBX1 wild 
type, a previously reported 1223delC mutant[43], or the c.1399-1428dup30 mutant. While the 
empty CMV vector did not significantly stain transfected cells, cells transfected with wild-
type TBX1 showed homogeneous nuclear localization as previously described. As a positive 
control we analyzed the c.1223delC mutation, which was previously characterized in detail 
and shown to result in cytoplasmatic localization of TBX1 due to the loss of a c-terminal 
nuclear localization signal.[43] Our results for the c.1223delC mutant confirm the published 
findings obtained with a different reporter system and prove the reliability of our assay. The 
30bp duplication in exon 9c (c.1399-1428dup30) resulted in protein aggregation in cytoplasm 
and nucleus, due to elongation of a polyalanine stretch. 
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Figure 4. Clinical photographs of the patient with the TBX1 c.1399-1428dup30 mutation. 
The facial phenotype of the 20 years old woman was neither considered suggestive of 
22q11.2 deletion nor any other syndrome, but the palpebral fissures were mildly upslanting 
and the chin was large and asymmetric. The columella was somewhat pointed. In addition 
there was clinodactyly of fingers and toes, with the middle fingers being most affected, and 
mild syndactyly of toes 2 and 3. 
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Tables 
Table 1. Primer sequences used to amplify and sequence all coding exons of the three TBX1 
isoforms (A, B. C) and exon/intron boundaries. 
TBX1 Orientation Sequence 
Fragment 
size 
Exon 1 F GAGCAGATGTCTCAGCCCAG 344bp 
 R CCACACTCCTCTTCACCTGC  
Exon 2 F CTGTCTCCCCGAGCCAGT 263bp 
 R CAAGAGCTGCCTCCACCTAC  
Exon 3 F GCAGCTCTCGCATTTCTGC 622bp 
 R GGCGGAGGATAGGTGTTAGGAG  
Exon 4 F GCTAAGCCAGGAAAGATGGAG 394bp 
 R CGGGTTGATCGGGCAGCATCGC  
Exon 5 F CAGAGGGTTCAATCTCACAGG  382bp 
 R GGATTCTACAGGCCTCTTAGG  
Exon 6 F CATTGCCAACTCAGACCTCAG  361bp 
 R CACAGCCTGCAGGTCTAAGC  
Exon 7 & 
8 F CTTGTCAGGGCAGCAGAAAGG 418bp 
 R TAGAGCGCGCACAGGGCC  
Seq Exon 
8 R GCGGAGAGAAGGCTCTTG  
Exon 9a F TCAGACACTGGACATTTGTGC 453bp 
 R ACTGGGAGTGTGACTCTATGGA  
Exon 9b F AGGCCACAAACACTTTGACC 264bp 
 R TTCCATCACAGCCTCTTCAC  
Exon 9c F GACTGGTCGGGGAACACC 692bp 
 R AACGTATTCCTTGCTTGCCC  
 
 
Table 2. Summary of genetic findings in 42 out of 230 patients with TOF 
 
n  % Gene/locus Mutation/Aberration Phenotype 
17 7.4 22q11.2 Common 3 Mb microdeletion 
(16x) 
Proximally nested 1.5 Mb deletion 
(1) 
DiGeorge-/VCFS spectrum 
12  5.2 Trisomy 21  47,XY,t(4;21)(q12;q11.2),+21 
46,XX,der (15;21)(p10;p10)+21 
47,XX/XY,+21 (7x) 
47,XY,+21 in female patient*  
100 K SNP array enh(21) (1x) 
Down syndrome; 
* Down syndrome and Swyer 
syndrome: AVSD, hypoplastic right 
ventricle, right aortic arch, external  
and internal genitalia (uterus) female, 
frequent infections,  
3 1.3 chromosomal 
aberrations 
other than 
trisomy 21 
der(19)(pter::p13.2-13.3::13.3-
qter) de novo 
height/weight <P3, mental retardation, 
impaired hearing, frequent infections, 
craniofacial dysmorphy, restrictive 
VSD, LAA, aberrant subclavian artery 
   del(21)(q22.3) de novo height/weight <P3, mental retardation, 
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cleft palate, inguinal hernias, hip 
dysplasia, LSVC, perimembr. VSD, 
additional VSD, juxtaductal 
coarctation, LAA, aberrant subclavian 
artery,  
   47,XXX height/weight > P97, scoliosis, frequent 
infections, long, spherical 
infundibulum, juxtaductal coarctation 
4/1
9 
test
ed  
1.7 Microaber-
rations other 
than 22q11.2 
deletion 
del(1)(p32.2p31.1), 14Mb, parents 
not available 
Mental retardation, height/lenght < P3, 
agenesis of corpus callosum, 
hydrocephalus, seizures, renal 
dysplasia, jejunal atresia, clubfoot, 
coronary arteries abnormal, LCA from 
RCA, RAA, right vertebral arteria from 
aortic arch 
   del(6)(q16.1q21), 12.80 Mb, de 
novo 
Mental retardation, behavioral 
problems, thymic aplasia,frequent 
infections, DORV 
   del(7)(p22.3p22.2), 1.50 Mb, de 
novo 
Mental retardation, cleft palate,  facial 
dysmorphism, scoliosis, DORV, RAA 
   del(19)(p13.11p12), 4.5 Mb and 
dup(19)(q13.1), 2.70 Mb, both de 
novo 
mental retardation, craniofacial 
anomalies, coronary artery anomalies 
(LAD from RCA) 
3 1.3 JAG1 c.2810G>A (p.R937Q) 
 
Alagille facies, mild mental retardation, 
RAA, singular origin of left subclavian 
artery, truncus bicaroticus 
   c.439C>T (p.Q147X), parents not 
available 
 
Alagille facies, severe mental 
retardation, hypernasality, dysplastic 
ears, flat nasal bridge, wide-set nipples, 
extrahepatic biliary atresia, peripheral 
pulmonary stenosis 
   c.2508_2509insTG 
(p.D837WfsX870) 
Alagille facies, premature birth, 
microcephaly, dystrophy, severe 
mental retardation, extrahepatic biliary 
atresia (liver transplantation at 2 years 
of age), juxtaductal coarctation, 
peripheral pulmonary stenosis, truncus 
bicaroticus 
2 0.9 NKX2.5 R25C Dextroposition of the aortia >50% from 
right ventricle, aberrant subclavian 
artery 
   R25C and 
46,XY,inv(5)(p14.2q13.1) 
Normal facies, no mental retardation, 
elongated infundibulum, LAA 
1 0.4 TBX1 
 
c.1399-1428dup30, excluded in 
mother, father not available 
Scoliosis, facial asymmetry, upslanting 
palpebral fissures, absent PV, isolated 
left pulmonary artery 
 
 
 
Table 3. Overview of structural polymorphisms and rare single nucleotide variants identified 
in 6 out of of 230 patients with TOF 
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n  % Gene/locus Mutation/Aberration Phenotype 
3 1.3 Structural 
polymorphisms 
45,XX,der(13;14)(q10;q10)pat 
Uniparental disomies 13 and 14 excluded 
Height/weight <P3, mental 
retardation, Dandy-Walker 
cyst, hydrocephalus, 
omphalocele, juxtaductal 
coarctation 
   inv(2)(p11.2q13) Typical TOF  
   inv(9)(p12q13) Typical TOF 
2 0.9 NKX2.5 C270Y, absent in controls, parents not tested Horseshoe kidney, mild 
pectus carinatus, MAPCA 
from the descending aorta, 
RAA without SAA 
 
 
  V315L, absent in controls, parents not tested Obesity, aberrant subclavian 
artery 
1 0.4 TBX1 P290S inherited from healthy father Absent PV, frequent 
infections 
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Table 4. Extracardiac abnormalities in 230 patients with TOF  
 
 all No 
genetic 
abnorm. 
Del 
22q11.2 
1 TBX1,  
2 
NKX2.5,  
3 JAG1  
Down Further 
chromosomal 
tions 
polymor-
phisms 
        
N (%) 230 182 
(79.1) 
17 (7.4) 6 (2.6) 12 (5.2) 7 (3.0) 6 (2.6) 
mean age (yrs) 
at inclusion in 
our study 
(range) 
10.9 
(0/34.0) 
10.9 
(0/34.0) 
7.4 
(0/21.8) 
8.5 
(0.4/16.4) 
14.7 
(0.9/32.4) 
7.9 
(0.3/14.3) 
18.2 
(3.5/33.5) 
mean time 
(yrs) post 
surgery 
(range) 
9.2 
(0.2/28.8) 
9.5 
(0.2/28.8) 
6.3 
(0/21.0) 
5.3 
(0/12.9) 
10.5 
(2.7/23.8) 
6.1 
(0.2/10.8) 
14.5 
(3.0/14.5) 
weight z-scores  
(min/max) 
-0.6 
(-11/5) 
-0.4  
(-
11.1/5.0) 
-0.9 
(-
5.2/2.2) 
-1.5 
(-6.3/0.9) 
-2.0 
(-3.7/-
0.5) 
-1.1 
(-5.0/2.2) 
-0.1 
(-2.8/1.8) 
height z-scores 
(min/max) 
-0.1 
(-5.8/9.6) 
0.07  
(-5.7/9.7) 
-0.6 
(-
4.1/1.4) 
-0.2 
(-3.3/2.8) 
-2.1 
(-3.8/-
0.2) 
-0.8 
(-5.7/3.1) 
-0.4 
(-2.4/0.8) 
CNS imaging 
performed (%) 
74 (32) 56 (31) 7 (41) 2 (33) 3 (25) 4 (57) 2 (33) 
CNS imaging 
pathologic (%) 
25 (11) 16 (9) 2 (12) 0  2 (17) 3 (43) 2 (33) 
mental retard. 
(%) 
       
no 163 (71) 151 (83) 3 (18) 3 (63) 1 0 5 (83) 
mild 55 (24) 28 (15) 14 (82) 2 (JAG1) 
(25) 
9 (82) 1 (14) 1 (17) 
severe 12 (5) 3 (2) 0 1 (JAG1) 
(12) 
2 (18) 6 (86) 0 
seizures 18 (8) 11 (6) 4 (24) 0 2 (17) 1 (14)  
velopharyngeal 
insufficiency 
12 (5) 3 (2) 8 (47) 1 (JAG1) 
(17%) 
0 0 0 
cleft palate 8 (3) 4 (2) 1 (6) 0 0 2 (29) 0 
impaired 
hearing 
10 (4) 7 (4) 0 0 2 (17) 1 (14) 0 
skeletal 
abnormality 
57 (25) 36 (20) 4 (24) 2 (2 
JAG1) 
(33) 
8 (73) 6 (86) 1 (17) 
genitourinary 
abnormalities 
29 (13) 19 (10) 3 (18) 0 3 (25) 2 (29)  2 (33) 
frequent 
infections 
=/>1/month 
38 (17) 26 (14) 5 (29) 0 3 (25) 3 (43) 1 (17) 
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Table 5 Cardiac phenotype in 230 patients with TOF 
 
 all No 
genetic 
abnorm. 
del 
22q11.2 
1 TBX1,  
2 
NKX2.5,  
3 JAG1 
Down Further 
chromosomal 
aberrations 
polymor-
phisms 
N (%) 230 182 (79) 17 (7.4) 6 (2.6) 12 (5.2) 7 (3.0) 6 (2.6) 
situs solitus 230 
(100) 
182 
(100) 
17 
(100) 
6(100) 12 (100) 7 (100) 6 (100) 
LSVC 22 (10) 20 (11) 1 (6) 0 0 1 (14) 0 
PAPVC 5 (2) 4 (22) 0 0 0 0 0 
PFO/ASD II 185 
(80) 
149 (82) 13 (76) 5 (83) 8 (67) 6 (86) 4 (66) 
ASD I 5 (2) 2 (1) 0 0 3 (25) 0 0 
sinus venosus 
ASD 
1 (0.4) 1 0 0 0 0 0 
Malalignment 
VSD 
226(98) 182 (88) 17 
(100) 
6 (100) 9 (75) 7 (100) 5 (83) 
AVSD 4 (2) 0 0 0 3 (25) 0 1 (17) 
additional 
VSDs 
20 (9) 16 (9) 0 1 TBX1 
(17) 
1 (8) 2 (29) 0 
infundibulum        
short 111 
(48) 
90 (49) 6 (35) 1 JAG1) 
(17) 
4 
(33) 
4 (57) 6 (100) 
elongated 71 (31) 57 (31) 5 (29) 2 
NKX2.5 
(33) 
5 
(42) 
2 (29) 0 
TOF-type 32 (14) 27 (15) 2 (12) 3 (1 
TBX1,  
2 JAG1) 
(50) 
0 0 0 
unknown 19 (8) 10 (5) 4 (24) 0 3 (25) 1(14) 1 (17) 
pulmonary 
stenosis 
       
predominantly 
valvular 
21 (9) 16 (9) 2 (12) 1 JAG1 
(17) 
1  
(8) 
0 1 (17) 
predominantly 
infundibular 
11 (5) 11 (6) 0 0 0 0 0 
combined 182 
(79) 
144 (79) 12 (71) 5 (83) 10 (83) 6 (86) 4 (67) 
unknown 10 (4) 7 (4) 2 (12) 0 0 1 (14) 0 
juxtaductal 
coarctation/ 
PA 
hypoplasia 
34 (15) 20 (11) 8 (47) 2 (JAG1) 
(33) 
0 3 (43) 1 (17) 
peripheral 
PA-stenosis 
14 (6) 9 (5) 2 (12) 2 (2 
JAG1) 
(33) 
0 0 1 (17) 
MAPCA        
yes 12 (5) 9 (5) 2 (12) 0 0 0 1 (17) 
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no 216 
(94) 
173 (95) 15 (88) 6 (100) 12 (100) 7 (100) 5 (83) 
unknown 2 (1) 2 (1) 0  0 0 0 0 
PDA        
yes 47  
(20) 
36 
(LAA17, 
RAA 
18) 
(20) 
3 (LAA 
1, RAA 
2) 
(18) 
0 2 
(LAA/RAA) 
(17) 
5  
(71) 
(4 LAA) 
1 (17) 
(LAA) 
no 21 (9) 15 (8) 2 (11) 1 (17) 2 (17) 0 1 (17) 
unknown 165 
(72) 
133 (58) 12 (71) 5 (83) 9 (75) 2 (29) 4 (67) 
additional 
cardiac 
defects 
       
absent PV 10 (4) 7 (4) 1 (6) 1 (TBX1) 
(17) 
0 0 1 (17) 
origin of the 
aorta > 50%  
from right 
ventricle 
14 (6) 9 (5) 2 (11) 1 
(NKX2.5) 
(17) 
0 2 (29) 0 
coronary 
arteries 
       
normal 203 
(88) 
158 (87) 16 (94) 6 (100) 12 (100) 5 (71) 6 (199) 
single 5 (2) 5 (3) 0 0 0 0 0 
accessory 13 (6) 12 (7) 1 (6) 0 0 0 0 
LAD from 
RCA 
9 (4) 7 (4) 0 0 0 2 (29) 0 
unknown 3 (1) 0 0 0 0 0 0 
long asc. 
aorta 
15 (7) 12 (7) 2 (12) 0 1 (8) 0 0 
aortic arch        
left 159 
(69) 
126 (68) 9 (53) 5 (83) 10 (83) 5 (71) 5 (83) 
right 71 (31) 58 (32) 8 (47) 1 (JAG1) 
(17) 
1 (8) 2 (29) 1 (17) 
subclavian 
artery 
anomalies 
31 
 
(13) 
17 (LAA 
6, RAA 
11) 
(9) 
9 (LAA 
3, RAA 
6) 
(53) 
1  
(NKX2.5, 
LAA 1) 
(17) 
1 (LAA) 
 
(8) 
2 (29)  
(2 LAA) 
 
 
1 (17) 
LAA  
aberrant 24 (10) 12 (7) 6 (35) 2 (33) 1 (8) 2 (17) 1 (17) 
isolation 7 (all 
RAA) 
(3) 
5 
(3) 
2 
(12) 
0 0 0 0 
distal ductal 
origin 
0 0 0 0 0 0 0 
CORSA 1 0 1 (6) 0 0 0 0 
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ASD (atrial septal defect); AVSD (atrioventricular septal defect); CORSA (cervical origin of 
the right subclavian artery); DORV (double outlet right ventricle); LAA (left aortic arch);  
LAD (left anterior descending coronary artery); LSVC (left superior vena cava); MAPCA 
(major aortopulmonary collateral arteries); PA (pulmonary artery); PAPVC (partial 
anomalous pulmonary venous connection; PDA (patent ductus arteriosus); PFO (persistent 
foramen ovale); RAA (right aortic arch); RCA (right coronary artery); SAA (subclavian artery 
anomaly); TOF (tetralogy of Fallot), VSD (ventricular septal defect) 
 
 
 
 
 
 
